Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth

NCT00685854 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

5

Enrollment

NIH

Sponsor class

Conditions

Macular Telangiectasia

Interventions

DRUG: Ranibizumab

Sponsor

National Eye Institute (NEI)